Feature|Videos|July 14, 2025

Strategies in Today’s Market for Pricing and Reimbursement Models

A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models that require strong value propositions, strategic planning, and significant upfront investment in data and stakeholder alignment.

In this episode, the panelists provide a candid look at how payers are increasingly open to innovative reimbursement structures—but only if the groundwork is thoughtfully laid. It’s not enough to pitch a novel payment model; manufacturers must bring solutions tied to the payer’s biggest challenges and be ready to share risk.

Key discussion topics include:

  • Designing outcome-based contracts aligned with payer data systems.
  • When and how to engage payer medical directors in model design.
  • Differences in feasibility across pharmacy and medical benefit products.
  • Why a strong value proposition must precede any innovative contract.

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.